1. Home
  2. ZYXI vs KPTI Comparison

ZYXI vs KPTI Comparison

Compare ZYXI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYXI
  • KPTI
  • Stock Information
  • Founded
  • ZYXI 1996
  • KPTI 2008
  • Country
  • ZYXI United States
  • KPTI United States
  • Employees
  • ZYXI N/A
  • KPTI N/A
  • Industry
  • ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZYXI Health Care
  • KPTI Health Care
  • Exchange
  • ZYXI Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • ZYXI 44.8M
  • KPTI 44.5M
  • IPO Year
  • ZYXI N/A
  • KPTI 2013
  • Fundamental
  • Price
  • ZYXI $1.50
  • KPTI $6.08
  • Analyst Decision
  • ZYXI Hold
  • KPTI Buy
  • Analyst Count
  • ZYXI 3
  • KPTI 6
  • Target Price
  • ZYXI $3.00
  • KPTI $39.80
  • AVG Volume (30 Days)
  • ZYXI 103.1K
  • KPTI 97.1K
  • Earning Date
  • ZYXI 10-23-2025
  • KPTI 11-04-2025
  • Dividend Yield
  • ZYXI N/A
  • KPTI N/A
  • EPS Growth
  • ZYXI N/A
  • KPTI N/A
  • EPS
  • ZYXI N/A
  • KPTI N/A
  • Revenue
  • ZYXI $144,808,000.00
  • KPTI $137,269,000.00
  • Revenue This Year
  • ZYXI N/A
  • KPTI $3.40
  • Revenue Next Year
  • ZYXI $7.07
  • KPTI $9.69
  • P/E Ratio
  • ZYXI N/A
  • KPTI N/A
  • Revenue Growth
  • ZYXI N/A
  • KPTI N/A
  • 52 Week Low
  • ZYXI $1.23
  • KPTI $3.51
  • 52 Week High
  • ZYXI $9.42
  • KPTI $16.95
  • Technical
  • Relative Strength Index (RSI)
  • ZYXI 42.77
  • KPTI 49.73
  • Support Level
  • ZYXI $1.44
  • KPTI $6.15
  • Resistance Level
  • ZYXI $1.55
  • KPTI $6.85
  • Average True Range (ATR)
  • ZYXI 0.09
  • KPTI 0.51
  • MACD
  • ZYXI 0.02
  • KPTI -0.16
  • Stochastic Oscillator
  • ZYXI 29.03
  • KPTI 16.10

About ZYXI Zynex Inc.

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: